The Direct Peptide Reactivity Assay (DPRA) is an in chemico method used to predict epidermal protein binding. Binding of epidermal proteins is the Molecular Initiating Event (MIE) on the sensitization Adverse Outcome Pathway (AOP). The DPRA uses HPLC to measure the depletion of synthetic peptides (Cysteine and Lysine) in solution following exposure to test chemicals.
OECD Test Guideline 442C is accepted for use. DPRA testing is considered validated by EURL-ECVAM, but should be used as part of an intergrated approach to testing and assessment (IATA) for discrimination between sensitizers and non-sensitizers for hazard classification and labelling.
MB Research has developed a non-animal Integrated Testing Strategy (ITS) for chemical-induced contact hypersensitivity (skin sensitization). This ITS provides a completely non-animal alternative to traditional testing methods. Together, our three assays address three key events on the skin sensitization adverse outcome pathway (AOP).
The In Vitro Sensitization Assay (IVSA) is a keratinocyte activation test. IVSA uses an ELISA method to measure IL-18 release from a topically treated reconstructed 3D human keratinocyte tissue model.
The Human Cell Line Activation Test (h-CLAT) is a dendritic cell activation test. The h-CLAT uses flow cytometry to measure CD86 and CD54 expression on treated THP-1 cells in culture.
The Direct Peptide Reactivity Assay (DPRA) is an in chemico method used to predict epidermal protein binding. Binding of epidermal proteins is the molecular initiating event on the AOP. The DPRA uses HPLC to measure the depletion of synthetic peptides in solution following exposure to test chemicals.
Below are MB Research services related to our In Vitro Toxicology Testing services.